ePrints

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Lookup NU author(s): Professor Gareth Veal, Dr David Jamieson, Katja Kuver

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Publication metadata

Author(s): Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marple M, Veal G, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi H, Beare S

Publication type: Article

Publication status: Published

Journal: Lancet Oncology

Year: 2017

Volume: 18

Issue: 10

Pages: 1397-1410

Print publication date: 01/10/2017

Online publication date: 04/09/2017

Acceptance date: 01/08/2017

Date deposited: 07/09/2017

ISSN (print): 1470-2045

ISSN (electronic): 1474-5488

Publisher: Elsevier

URL: https://doi.org/10.1016/S1470-2045(17)30622-8

DOI: 10.1016/S1470-2045(17)30622-8

Altmetrics

Funding

Share